Paper Details

  1. Home
  2. Paper Details

Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.

Author: BauerTodd M, CalellaAnna Maria, FelipEnriqueta, GotoYasushi, KimDong-Wan, LiuGeoffrey, MazieresJulien, MokTony, PeltzGerson, PolliAnna, ShawAlice T, SolomonBenjamin J, ThurmHolger, de MarinisFilippo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
CommentA short article/note that provides an opinion/perspective/interpretation on a published paper/topic.

Overview

This study, known as CROWN, compared the effectiveness of lorlatinib and crizotinib in treating untreated non-small cell lung cancer that had spread to other parts of the body, in patients with ALK gene mutations. The study found that lorlatinib was more effective than crizotinib, with participants taking lorlatinib twice as likely to be alive without tumor growth after a year of treatment. Lorlatinib also led to a higher rate of tumor shrinkage (76%) compared to crizotinib (58%). While lorlatinib had some side effects like increased cholesterol, swelling, and weight gain, it was overall associated with fewer deaths and tumor growth compared to crizotinib.
Paper Details　
Original Abstract of the Article :
This is a summary of a research study (known as a clinical trial) called CROWN. The study tested two medicines called lorlatinib and crizotinib in participants with untreated non-small cell lung cancer that had spread to other parts of their body. All those who took part had changes in a gene called...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2217/fon-2021-0904

データ提供：米国国立医学図書館（NLM）

Lorlatinib vs. Crizotinib: A Race to the Finish Line in ALK+ Lung Cancer

The fight against non-small cell lung cancer (NSCLC) is a relentless race against time. This clinical trial, known as CROWN, compared two promising drugs - lorlatinib and crizotinib - in patients with advanced NSCLC that had a specific genetic alteration called ALK. The researchers wanted to see which drug could help these patients live longer and keep their tumors from growing.

Lorlatinib Emerges as the Front-Runner

The results were clear: lorlatinib outperformed crizotinib in terms of survival and tumor control. After one year of treatment, patients taking lorlatinib were twice as likely to be alive without their tumors growing. Lorlatinib also shrank tumors in a greater percentage of patients, including those with brain metastases. These results suggest that lorlatinib could be a powerful new weapon in the fight against ALK+ NSCLC.

A New Hope for Lung Cancer Patients

The CROWN study provides a glimmer of hope for patients with ALK+ NSCLC. Lorlatinib's impressive results demonstrate that we are making progress in developing more effective treatments for this challenging disease. It's important to remember that all treatments have potential side effects, but the study found that lorlatinib's side effects were generally manageable. If you're a patient with ALK+ NSCLC, discussing lorlatinib with your doctor is a crucial step in navigating your treatment journey.

Dr. Camel's Conclusion

In the race against cancer, lorlatinib has emerged as a strong contender. This study highlights the importance of personalized medicine, where treatments are tailored to the specific genetic profiles of patients. With continued research and innovation, we are moving closer to the finish line in the fight against lung cancer.

Date :
  1. Date Completed 2021-11-17
  2. Date Revised 2021-11-17
Further Info :

Pubmed ID

34585621

DOI: Digital Object Identifier

10.2217/fon-2021-0904

Related Literature

Article Analysis
・Side Effects of lorlatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.